Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?

被引:26
作者
Inal, Ali [1 ]
Kaplan, M. Ali [1 ]
Kucukoner, Mehmet [1 ]
Urakci, Zuhat [1 ]
Kilinc, Faruk [2 ]
Isikdogan, Abdurrahman [1 ]
机构
[1] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey
[2] Dicle Univ, Div Endocrinol, Diyarbakir, Turkey
关键词
Diabetes mellitus; Non-small cell lung; cancer; Prognostic factors; COLORECTAL-CANCER; LONGER SURVIVAL; GLUCOSE LEVEL; RISK; NSCLC; PREVALENCE; MORTALITY; IMPACT; BLOOD;
D O I
10.1016/j.rppneu.2013.09.001
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: It has been demonstrated that there are a lot of different prognostic factors which Non-small cell lung are worthy of consideration whereas diabetes mellitus (DM) has not been clearly or consistently identified as a prognostic value in advanced non-small cell lung cancer (NSCLC). The aim Prognostic factors of this study was to investigate the prognostic significance of the characteristics of patients in advanced NSCLC. Specifically, we investigated the impact of DM for progression-free survival (PFS) and overall survival (OS) in patients receiving first-line platinum-based doublets chemotherapy. Methods: We retrospectively reviewed 442 patients with advanced NSCLC. DM and other potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Result: The results of univariate analysis for OS were identified as having prognostic significance: performance status (p < 0.001), stage (p < 0.001), DM (p < 0.001), liver metastasis (p = 0.02) and brain metastasis (p < 0.001). Stage, diabetes mellitus, and liver metastasis were identified as having prognostic significance for PFS. Multivariate analysis showed that poor performance status, presence of DM and advanced stage were considered independent negative prognostic factors for OS (p 0.001, p < 0.001 and p < 0.001 respectively). Furthermore, DM and stage were considered independent negative prognostic factors for PFS (p 0.005 and p 0.001 respectively). Conclusion: In conclusion, DM at the time of diagnosis was associated with the negative prognostic importance for PFS and OS in the advanced stage patients who were receiving first-line platinum-based doublets chemotherapy. In addition poor performance status and advanced stage were identified as negative prognostic factors. (c) 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 35 条
[1]  
[Anonymous], 2007, ARCH ONCOLOGY, DOI DOI 10.2298/AOO0702019V
[2]  
[Anonymous], 2012, CLIN PRACT GUID ONC
[3]   Cancer incidence and mortality in Europe, 2004 [J].
Boyle, P ;
Ferlay, J .
ANNALS OF ONCOLOGY, 2005, 16 (03) :481-488
[4]   Long-term risk of malignant neoplasm associated with gestational glucose intolerance [J].
Dawson, SI .
CANCER, 2004, 100 (01) :149-155
[5]   Diabetes is associated with longer survival rates in patients with malignant tumors [J].
De Giorgio, R ;
Barbara, G ;
Cecconi, A ;
Corinaldesi, R ;
Mancini, AM .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (14) :2217-2217
[6]   The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence [J].
El-Serag, HB ;
Hampel, H ;
Javadi, F .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) :369-380
[7]   Diabetes mellitus and risk of endometrial cancer: a meta-analysis [J].
Friberg, E. ;
Orsini, N. ;
Mantzoros, C. S. ;
Wolk, A. .
DIABETOLOGIA, 2007, 50 (07) :1365-1374
[8]   Protective effect of diabetes against metastasis in patients with non-small cell lung cancer [J].
Hanbali, Amr ;
Al-Khasawneh, Khaled ;
Cole-Johnson, Christine ;
Divine, George ;
Ali, Haytham .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (05) :513-513
[9]   Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus [J].
Hatlen, Peter ;
Gronberg, Bjorn Henning ;
Langhammer, Arnulf ;
Carlsen, Sven M. ;
Amundsen, Tore .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) :1810-1817
[10]   Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials [J].
Hotta, Katsuyuki ;
Fujiwara, Yoshiro ;
Kiura, Katsuyuki ;
Takigawa, Nagio ;
Tabata, Masahiro ;
Ueoka, Hiroshi ;
Tanimoto, Mitsune .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) :402-407